Turkish genomics healthcare company Genoks and healthcare technology company Velsera have teamed up to advance cancer diagnostics and treatment in Turkey and nearby regions.
The strategic partnership combines Genoks’ expertise in genomics with Velsera’s advanced Clinical Genomics Workspace (CGW).
CGW is an advanced platform designed for comprehensive analysis of data obtained from solid tissue and liquid tumours, along with haematological cancer samples.
Genoks will leverage Velsera’s capabilities in genomic analysis and data interpretation.
The genomics company will integrate CGW into its cancer diagnostic services to enhance its ability to accurately detect and characterise various types of cancer.
Genoks clinical geneticist Yunus Alp said: “We are thrilled to partner with Velsera in our shared mission to revolutionise cancer diagnostics and treatment in Turkey and beyond.
“Together, we are poised to make a significant impact in the fight against cancer, empowering clinicians with precise insights to guide treatment decisions and improve patient outcomes.”
The CGW platform is customised for physicians and clinical laboratory professionals specialising in oncology and inherited diseases.
It aims to dismantle obstacles hindering the establishment or growth of their Next-Generation Sequencing (NGS) testing programs.
CGW helps molecular diagnostics experts worldwide, working in physician-owned laboratories, large hospitals, or reference labs.
Through the collaboration, Genoks aims to advance its position in Turkish oncology diagnostics.
It will provide patients and healthcare providers with advanced testing solutions for precise and personalised cancer care.
Velsera’s advanced solutions will help Genoks deliver precise and actionable insights, enabling clinicians to make informed treatment decisions tailored to each patient’s unique genetic profile.
Furthermore, the collaboration is anticipated to advance cancer research and elevate the standard of patient care, said the healthcare technology company.
